AT9283

CHF 96.00
In stock
SYN-1011-M0011 mgCHF 96.00
SYN-1011-M0055 mgCHF 180.00
SYN-1011-M01010 mgCHF 299.00
SYN-1011-M05050 mgCHF 886.00
SYN-1011-M100100 mgCHF 1'436.00
 
More Information
Product Details
Synonyms AT-9283
Product Type Chemical
Properties
Formula C19H23N7O2
MW 381.4
CAS 896466-04-9
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO or ethanol.
Declaration Manufactured by SynKinase.
Other Product Data Target: Aurora A | Kinase Group: Other | Substrate: Serine-Threonine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key LOLPPWBBNUVNQZ-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Aurora kinases play a key role in the regulation of mitosis and in recent years have become attractive targets for the treatment of cancer. AT9283 is a powerful inhibitor of Aurora A and B kinases as well as several other important kinases including JAK2 and Abl (T315I). AT9283 has also been shown effective in mouise xenograft models and has been studied as a possible clinical candidate. Effective IC(50) doses for Aurora kinases are in the low 2-3nM range, and inhibition of a number of other kinases including JAK2 has been reported at 1-10nM.
Product References
  1. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity: S. Howard, et al.; J. Med. Chem. 52, 379 (2009)
  2. Discovery and development of aurora kinase inhibitors as anticancer agents: J.R. Pollard & M. Mortimore; J. Med. Chem. 52, 2629 (2009)
  3. Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors: Y. Zheng, et al.; Bioorg. Med. Chem. Lett. 23, 3523 (2013)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.